Conjugate Vaccine Market 2023 Report By Key Companies, Regional Analysis And Forecast 2032

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company's Conjugate Vaccine Global Market Report 2023 identifies increase in the use of conjugate vaccines for adults as the major driver for the conjugate vaccine market's growth in the forecast period. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body's defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response.

The global conjugate vaccine market size is expected to grow from $14.69 billion in 2022 to $16.77 billion in 2023 at a compound annual growth rate (CAGR) of 14.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global conjugate vaccine market size is expected to reach $27.22 billion in 2027 at a CAGR of 12.9%.

Download Free Sample Of Conjugate Vaccine Market Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp
Major competitors in the conjugate vaccine market are Sanofi S.A, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Biological E. Limited, Bavarian Nordic A/S.

A key trend in the conjugate vaccine market includes innovation in conjugate vaccines. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Read More On The Global Conjugate Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

The conjugate vaccine market is segmented -
• By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

• By Pathogen: Bacterial, Viral

• By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

• By Patient: Pediatric, Adults

• By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the conjugate vaccine market.

The Business Research Company's "Global Conjugate Vaccine Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Conjugate Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

The Table Of Content For The Conjugate Vaccine Market Include:
1. Executive Summary
2. Conjugate Vaccine Market Characteristics
3. Conjugate Vaccine Market Trends And Strategies
4. Conjugate Vaccine Market - Macro Economic Scenario
5. Conjugate Vaccine Market Size And Growth
……
26. Africa Conjugate Vaccine Market
27. Conjugate Vaccine Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Conjugate Vaccine Market
29. Conjugate Vaccine Market Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.